Chen Minming, Hao Yu, Ling Sisi, Yang Hongchao, Li Quguang, Wu Yumin, Wang Chunjie, Xu Yuchun, Yan Yifan, Gao Juxin, Li Chunyan, Feng Liangzhu, Liu Zhuang
Institute of Functional Nano & Soft Materials (FUNSOM), Jiangsu Key Laboratory for Carbon-Based Functional Materials & Devices, Soochow University, Suzhou 215123, China.
CAS Key Laboratory of Nano-Bio Interface, Division of Nanobiomedicine and i-Lab, Suzhou Institute of Nano-Tech and Nano-Bionics, Chinese Academy of Sciences, Suzhou 215123, China.
ACS Nano. 2025 Feb 18;19(6):5979-5994. doi: 10.1021/acsnano.4c10146. Epub 2025 Feb 4.
Autologous cancer vaccines represent a promising strategy to effectively suppress postoperative tumor relapse by eliciting tumor-specific immune responses that highly rely on the efficient internalization and lymph node-targeting delivery of vaccines. Herein, we report an autologous nanovaccine obtained by sequentially incorporating tumor plasma membrane proteins into liposomes, termed tumosomes, and chelating it with metallo-agonist of manganese ions. The yielded Mn-tumosomes with a positively charged surface exhibited significantly enhanced internalization by dendritic cells and enhanced lymph node targeting capacity, the latter of which is indicated by the near-infrared II fluorescence of silver sulfide nanoprobes labeled on their lipid bilayers. As a result, vaccination with Mn-tumosomes elicited potent tumor-specific CD8+ T cells to suppress the growth of challenged allogeneic tumors more effectively than vaccination bolus injection of plain tumosomes and commercial immune agonists. Furthermore, with the excised tumor mass as the source of whole tumor cell antigens, the as-prepared autologous Mn-tumosomes effectively suppressed the growth of both residual tumor masses and spontaneously formed metastatic tumors, particularly in combination with anti-PD-1 immunotherapy. This work highlights a metal coordination based strategy to fabricate personalized whole-tumor cell nanovaccines with superior lymph node targeting and cellular uptake efficacy for the immunotherapeutic suppression of postoperative tumor relapse.
自体癌症疫苗是一种很有前景的策略,可通过引发高度依赖疫苗有效内化和淋巴结靶向递送的肿瘤特异性免疫反应,来有效抑制术后肿瘤复发。在此,我们报告了一种自体纳米疫苗,它是通过将肿瘤质膜蛋白依次掺入脂质体(称为肿瘤体)并与锰离子的金属激动剂螯合而获得的。产生的表面带正电荷的锰 - 肿瘤体表现出树突状细胞对其内化的显著增强以及淋巴结靶向能力的增强,脂质双层上标记的硫化银纳米探针的近红外 II 荧光表明了后者。结果,与单纯注射肿瘤体和商业免疫激动剂相比,用锰 - 肿瘤体进行疫苗接种能引发强效的肿瘤特异性 CD8 + T 细胞,更有效地抑制受挑战的同种异体肿瘤的生长。此外,以切除的肿瘤块作为全肿瘤细胞抗原的来源,所制备的自体锰 - 肿瘤体有效地抑制了残留肿瘤块和自发形成的转移瘤的生长,特别是与抗 PD - 1 免疫疗法联合使用时。这项工作突出了一种基于金属配位的策略,用于制造具有卓越淋巴结靶向性和细胞摄取功效的个性化全肿瘤细胞纳米疫苗,以用于免疫治疗抑制术后肿瘤复发。